LysSYL: a broad-spectrum phage endolysin targeting Staphylococcus species and eradicating S. aureus biofilms
Background Staphylococcus aureus and its single or mixed biofilm infections seriously threaten global public health. Phage therapy, which uses active phage particles or phage-derived endolysins, has emerged as a promising alternative strategy to antibiotic treatment. However, high-efficient phage therapeutic regimens have yet to be established. Results In this study, we used an enrichment procedure to isolate phages against methicillin-resistant S. aureus (MRSA) XN108. We characterized phage SYL, a new member of the Kayvirus genus, Herelleviridae family. The phage endolysin LysSYL was expressed. LysSYL demonstrated stability under various conditions and exhibited a broader range of efficacy against staphylococcal strains than its parent phage (100% vs. 41.7%). Moreover, dynamic live/dead bacterial observation demonstrated that LysSYL could completely lyse MRSA USA300 within 10 min. Scan and transmission electron microscopy revealed evident bacterial cell perforation and deformation. In addition, LysSYL displayed strong eradication activity against single- and mixed-species biofilms associated with S. aureus. It also had the ability to kill bacterial persisters, and proved highly effective in eliminating persistent S. aureus when combined with vancomycin. Furthermore, LysSYL protected BALB/c mice from lethal S. aureus infections. A single-dose treatment with 50 mg/kg of LysSYL resulted in a dramatic reduction in bacterial loads in the blood, liver, spleen, lungs, and kidneys of a peritonitis mouse model, which resulted in rescuing 100% of mice challenged with $ 10^{8} $ colony forming units of S. aureus USA300. Conclusions Overall, the data provided in this study highlight the strong therapeutic potential of endolysin LysSYL in combating staphylococcal infections, including mono- and mixed-species biofilms related to S. aureus..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:23 |
|---|---|
| Enthalten in: |
Microbial cell factories - 23(2024), 1 vom: 25. März |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Liu, He [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| BKL: | |
|---|---|
| Themen: |
| Anmerkungen: |
© The Author(s) 2024 |
|---|
| doi: |
10.1186/s12934-024-02359-4 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR055294669 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR055294669 | ||
| 003 | DE-627 | ||
| 005 | 20240327064931.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240327s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s12934-024-02359-4 |2 doi | |
| 035 | |a (DE-627)SPR055294669 | ||
| 035 | |a (SPR)s12934-024-02359-4-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |a 570 |q VZ |
| 084 | |a 44.00 |2 bkl | ||
| 100 | 1 | |a Liu, He |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a LysSYL: a broad-spectrum phage endolysin targeting Staphylococcus species and eradicating S. aureus biofilms |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s) 2024 | ||
| 520 | |a Background Staphylococcus aureus and its single or mixed biofilm infections seriously threaten global public health. Phage therapy, which uses active phage particles or phage-derived endolysins, has emerged as a promising alternative strategy to antibiotic treatment. However, high-efficient phage therapeutic regimens have yet to be established. Results In this study, we used an enrichment procedure to isolate phages against methicillin-resistant S. aureus (MRSA) XN108. We characterized phage SYL, a new member of the Kayvirus genus, Herelleviridae family. The phage endolysin LysSYL was expressed. LysSYL demonstrated stability under various conditions and exhibited a broader range of efficacy against staphylococcal strains than its parent phage (100% vs. 41.7%). Moreover, dynamic live/dead bacterial observation demonstrated that LysSYL could completely lyse MRSA USA300 within 10 min. Scan and transmission electron microscopy revealed evident bacterial cell perforation and deformation. In addition, LysSYL displayed strong eradication activity against single- and mixed-species biofilms associated with S. aureus. It also had the ability to kill bacterial persisters, and proved highly effective in eliminating persistent S. aureus when combined with vancomycin. Furthermore, LysSYL protected BALB/c mice from lethal S. aureus infections. A single-dose treatment with 50 mg/kg of LysSYL resulted in a dramatic reduction in bacterial loads in the blood, liver, spleen, lungs, and kidneys of a peritonitis mouse model, which resulted in rescuing 100% of mice challenged with $ 10^{8} $ colony forming units of S. aureus USA300. Conclusions Overall, the data provided in this study highlight the strong therapeutic potential of endolysin LysSYL in combating staphylococcal infections, including mono- and mixed-species biofilms related to S. aureus. | ||
| 650 | 4 | |a Phage |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Endolysin |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Biofilms |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Persisters |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Wei, Xuemei |4 aut | |
| 700 | 1 | |a Wang, Zhefen |4 aut | |
| 700 | 1 | |a Huang, Xiaonan |4 aut | |
| 700 | 1 | |a Li, Mengyang |4 aut | |
| 700 | 1 | |a Hu, Zhen |4 aut | |
| 700 | 1 | |a Zhang, Kexin |4 aut | |
| 700 | 1 | |a Hu, Qiwen |4 aut | |
| 700 | 1 | |a Peng, Huagang |4 aut | |
| 700 | 1 | |a Shang, Weilong |4 aut | |
| 700 | 1 | |a Yang, Yi |4 aut | |
| 700 | 1 | |a Wang, Yuting |4 aut | |
| 700 | 1 | |a Lu, Shuguang |4 aut | |
| 700 | 1 | |a Rao, Xiancai |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Microbial cell factories |d BioMed Central, 2002 |g 23(2024), 1 vom: 25. März |w (DE-627)SPR028553225 |w (DE-600)2091377-1 |x 1475-2859 |7 nnns |
| 773 | 1 | 8 | |g volume:23 |g year:2024 |g number:1 |g day:25 |g month:03 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1186/s12934-024-02359-4 |z kostenfrei |3 Volltext |
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 936 | b | k | |a 44.00 |q VZ |
| 951 | |a AR | ||
| 952 | |d 23 |j 2024 |e 1 |b 25 |c 03 | ||